Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Significant growth opportunities fuelled by strong R&D
pipeline across all four strategic focus areas
PHASE 1
LAI287QW basal insulin
NN1406 Mealtime insulin
G530S Glucagon analogue
NN9838 Amylin analogue
NN9747 PYY analogue
PHASE 2
Semaglutide - QD GLP-1
Anti-IL-21 and liraglutide
Semaglutide QD GLP-1
PHASE 3
Semaglutide - QW GLP-1
OG217SC Oral GLP-1
N8-GP Long-acting rFVIII
Somapacitan - QW GH
NN9277
GG-co-agonist
NN7415 Concizumab
Diabetes
Obesity
Haemophilia
Growth disorders
1 Approved in all triad markets (US, EU and Japan), unless noted
GG: Glucagon GLP-1
changing
diabetes®
SUBMITTED
XultophyⓇ (US)
Faster-acting insulin aspart
N9-GP Long-acting rFIX
APPROVED¹
Levemir®
NovoRapidⓇ
NovoMix®
Tresiba®
RyzodegⓇ
XultophyⓇ (EU)
VictozaⓇ
SaxendaⓇ
NovoSevenⓇ
NovoEight®
NovoThirteenⓇ
Norditropin®
Slide 28
novo nordiskView entire presentation